Phenotypic Variants of Patients with Progressive Supranuclear Palsy

Murat GÜLTEKİN

Department of Neurology, Erciyes University School of Medicine, Kayseri, Turkey

ABSTRACT

Introduction: Progressive supranuclear palsy (PSP) is a commonly observed disease among Parkinson plus syndromes, and its early and accurate diagnosis is usually not possible. PSP is currently reported to have eight different subtypes. This study aims to determine the phenotypic subtypes of PSP and reveal their accompanying characteristics.

Methods: Eighteen patients who were diagnosed as having PSP according to the National Institute for Neurological Disorders and Society for PSP (NINDS-SPSP) criteria were included in the study. Initial symptoms of the patients, their initial diagnosis, course of the disease with time, cranial images, and predominant clinical features were assessed with regard to the subtypes of PSP.

Results: The mean age of the patients was 65.83 years. According to the NINDS-SPSP criteria, all patients were diagnosed as having probable PSP. An evaluation of the patients with respect to the subtypes showed that five different subtypes had predominant characteristics. Richardson's syndrome was found to be the most common subtype.

Conclusion: Classifying PSP with regard to its phenotypes may be useful for informing clinicians about the diverse clinical presentations of PSP, thereby possibly improving the diagnostic sensitivity of the disease.

Keywords: Progressive supranuclear palsy, phenotype, variant

Cite this article as: Gültekin M. Phenotypic Variants of Patients with Progressive Supranuclear Palsy. Arch Neuropsychiatry 2020;57:61–64.

INTRODUCTION

Parkinson's disease (PD) is the second most common neurodegenerative disease. Progressive supranuclear palsy (PSP) is the most commonly observed disease among Parkinson plus syndromes (1). From its onset, PSP cannot usually be accurately diagnosed, especially by inexperienced neurologists (2). The NINDS-SPSP criteria are used for the clinical diagnosis of PSP (3). Clinical characteristics include early onset postural instability, vertical gaze palsy, symmetrical parkinsonism with serious axial symptoms and non-responsive to L-dopa, pseudobulbar dysarthria, dysphagia, and frontal dysfunction. The majority of cases are sporadic (4). The incidence of PSP is 4%–6% among all parkinsonisms (5). PSP is a tauopathy disorder, and neuropathology is needed for its definite diagnosis. Neurofibrillary tangles are present in several subcortical areas such as the substantia nigra, subthalamic nucleus, and midbrain.

Data regarding the subtypes of PSP is increasing in the literature (6,7). According to the data present in the literature, there are eight different subtypes of PSP, namely PSP with Richardson's syndrome (PSP-RS), PSP with predominant parkinsonism (PSP-P), PSP with pure akinesia with gait freezing (PSP-PAGF), PSP with corticobasal syndrome (PSP-CBS), PSP with predominant language and speech dysfunction (PSP-PNFA and PSP-AOS), PSP with predominant frontotemporal dysfunction (PSP-FTD), PSP with cerebellar ataxia (PSP-C), and PSP with primary lateral sclerosis (PSP-PLS) (8). The most significant challenge regarding the diagnosis of PSP-P arises owing to the phenotype. This is not usually possible to diagnose PSP type until the later stages of the disease due to lack of decisive biomarkers.

In a recent article published by the PSP Study Group of Movement Disorder Society, four clinical areas (ocular dysfunction, postural unbalance, akinesia, and cognitive function impairment) are recommended for the clinical differential diagnosis of PSP. In addition, three clinical features contribute to the diagnostic accuracy at different stages. Accordingly, specific combinations of these characteristics describe the diagnosis criteria with under three subtypes (probable PSP, possible PSP, and suggestive PSP). Imaging features (midbrain atrophy or hypometabolism and/or postsynaptic striatal dopaminergic degeneration) and clinical features are among the supporting characteristics (9). Thus, there is needed to optimize for the accurate, early, and specific diagnosis of PSP.

This study aimed to determine the phenotypic subtypes of PSP and reveal their accompanying characteristics.

METHODS

Patients who were diagnosed as having PSP at Erciyes University School of Medicine between June 2014 and December 2016 were included in this study. The approval of the local ethics committee and the consent of the patients were obtained.

Medical records of the patients who were followed up owing to the diagnosis of PSP were retrospectively assessed, and the latest clinical characteristics were noted. The NINDS-SPSP criteria were considered for the diagnosis of PSP (3). Clinical characteristics included the onset of disease at an age of ≥ 40 years, slower vertical eye movements or vertical

gaze palsy, significant postural instability or falls during the first year, and accompanying symmetrical parkinsonism. In addition, cranial magnetic resonance (MR) images of all patients were examined. Conventional 1.5-Tesla MR imaging (MRI) sections were collected. The patients with evident rostral midbrain atrophy and hummingbird sign on MRI were included in this study (10). The criterion for the midbrain-to-pons ratio was $<0.124 \text{ mm}^2$ (11). Patients with PSP who met the abovementioned characteristics were included in the study.

Each patient was extensively examined by a neurologist who had experience with movement disorders. Initial symptoms of the patients, their initial diagnosis, treatment responses, course of the disease with time, additional symptoms, cranial images, disabling symptoms, and predominant clinical characteristics were assessed according to the subtypes of PSP.

Statistics Analysis

Demographical and clinical data of the participants that were obtained within the scope of the study were evaluated using descriptive statistics. Mean $\pm$ SD and median 25 and 75 percentile values are presented. Results of frequency analysis applied to certain data are given in Table 1, 2. The Statistical Package for the Social Sciences 15.0 (SPSS Inc.; Chicago, IL, USA) was used for analysis.

RESULTS

We included 18 patients with PSP in this study. The mean age of the patients was 65.83 years. The mean age at onset was 61.78 (51–70) years. Furthermore, the mean disease duration was 4.06 (3–8) years. According to the NINDS-SPSP criteria, all patients were diagnosed as having probable PSP. All patients had postural instability that was characterized by falls within the first year. Subsequently, in the next years, they developed supranuclear gaze palsy and slowness in vertical saccades.

Considering the clinical characteristics of the 18 patients with PSP, only two patients were accurately diagnosed as having PSP diagnosis on the basis of the onset characteristics. Thirteen patients were followed up owing to a diagnosis of PD, and the remaining three patients were followed up for a diagnosis of ataxia. Most of the patients did not have tremors and cervical dystonia. However, most patients had eye opening apraxia and eyelid dystonia. The majority of patients (14/18) were non-responsive to L-dopa, and postural instability was a major problem. The patients were not followed up at the same center and by the same doctor regularly from the onset of the disease until admission to our polyclinic. Three patients were followed up for a diagnosis of ataxia. Clinicians might have diagnosed the patients as having ataxia owing to postural instability and frequent falls. Despite this, no cerebellar atrophy was observed on the MR images of the patients. The clinical characteristics of the patients are given in Table 1.

An evaluation of patients with PSP with respect to subtypes showed that five different subtypes were predominant characteristics. It is necessary to underline the fact that all patients had symmetrical parkinsonism, postural instability, and other clinical PSP characteristics together with predominant characteristics. However, the predominant subtypes were determined according to the major presentation during clinical examination and the course of the disease. PSP-RS was found to be the most common subtype. Atrophy of the midbrain with the preservation of the pons constitutes a specific pattern that resembles a hummingbird or penguin and is known as the hummingbird sign, which is sometimes also called the penguin silhouette sign, as observed on midsagittal sections. The hummingbird sign has a very high specificity (100%; sensitivity, 97.8%). Cranial MRI of a patient with PSP-RS is shown in Figure 1a and 1b. The predominant subtypes

Table 1. Clinical features of patients with PSP

First diagnosis	N	%
PSP	2	11.1
PD	13	72.2
Ataxia	3	16.7
L-Dopa response		
Yes (temporary)	4	22.2
No	14	72.8
Tremor		
No	10	55.6
Unilateral	2	11.1
Bilateral	6	33.3
Cervical dystonia		
Yes	4	22.8
No	14	77.2
Vertical gaze palsy		
Yes	18	100
No	0	0
Difficulty with eye opening		
No	5	27.8
Apraxia	8	44.4
Dystonia	5	27.8
RBD		
Yes	12	66.7
No	6	33.3

PSP: progressive supranuclear palsy; PD: parkinson's disease; RBD: REM sleep behavior disorder

Table 2. Subtypes of PSP

PSP subtypes	N	%
PSP-RS	7	38.9
PSP-P	3	16.7
PSP-PAGF	2	11.1
PSP-FTD	4	22.2
PSP-AOS and PSP-PNFA	2	11.1

PSP: progressive supranuclear palsy; PSP-RS: PSP with Richardson's syndrome; PSP-P: PSP with predominant parkinsonism; PSP-PAGF: PSP with pure akinesia with gait freezing; PSP-AOS and PSP-PNFA: PSP with predominant speech and/or language dysfunction; PSP-FTD: PSP with predominant frontotemporal dysfunction

PSP-CBS, PSP-C, and PSP-PLS were not observed in our patients. The PSP subtypes of our patients are given in Table 2.

The hummingbird sign was demonstrated on MR images of all patients. Moreover, frontoparietal atrophy was observed in patients with PSP-FTD. Frontal lobe dementia signs (behavior change, impairment in executive functions, inhibition, etc.) and parkinsonism were also observed. All patients considered postural instability to be a disabling symptom, which worsened over the years. Therefore, the patients used support devices such as a walking stick, walker, and wheelchair to walk.

DISCUSSION

In this study, other clinical characteristics of patients with PSP and their predominant clinical characteristics were examined. We showed that

Figure 1. a, b. (a) The preservation of the pons constitutes a specific pattern that resembles a hummingbird sign or a penguin (sagittal section) is seen on MRI (b) Midbrain atrophy with the enlargement of the third ventricle (axial section) is seen on MRI

the characteristics of multiple clinical phenotypes may be present in a patient. The majority of patients (16/18) also did not receive an accurate diagnosis. In addition to initial clinical symptoms, the subtypes of PSP show differences with regard to the clinical course.

Accurately diagnosing PSP on the basis of its heterogeneous clinical course and predominant characteristics was difficult. Dugger et al. (12) assessed 64 patients who were diagnosed as having pathologically proven PSP and found that 36% of the patients had concomitant Alzheimer's dementia, 20% had PD, 1% had Lewy body dementia, 44% had argyrophilic grains, 52% had cerebral white matter rarefaction, and 25% had cerebral amyloid angiography. As can be observed in this study, the clinical presentation of PSP greatly differs. O'Sullivan et al. (13) examined 110 patients who were pathologically confirmed to have PSP. The authors also showed that frequent falls occurred 3.9 (± 2.5) years from the onset of the disorder. Also, they showed 4.2 (± 2.9) years for cognitive deterioration, 6 (± 2.5) years for speech defects to incomprehensibility, 6.4 (± 2.4) years for dysphagia, and 6.4 (± 2.7) years for being wheelchair-bound.

Owing to the increasing number of studies in the literature, predominant characteristics of the subtypes of PSP are more clearly revealed (1). Akinetic rigid symptoms that are resistant to levodopa treatment are seen in PSP-RS. Axial muscles are affected and it lead to the tendency to fall back. Also, vertical gaze palsy is observed in the initial phase of the PSPRS. Apathy, pseudobulbar speech, aphasia, and deteriorations in executive functions are also observed (14). PSP-P is presented by parkinsonism with asymmetrical onset. Distinguishing PSP-P from PD until the onset of vertical gaze disorder is difficult (15). PSP-PAGF is characterized by sudden and temporary freezings that are observed without tremor and rigidity; this can be deemed typical for an underlying PSP neuropathology (16). Sometimes, the onset of the disease may be dominated by clinical symptoms that are suitable for the behavioral and language variants as in PSP-FTD or PSP-PNFA (17,18). The underlying pathologies of PSP-CBS are diverse, and 70% of patients present tauopathy. PSP-CBS accounts for only 4% of all cases with PSP (19,20). PSP-C is more commonly observed in Japan, and patients have neural loss in cerebellar dentate nucleus and gliosis (21). PSP-PLS is a progressive disorder that is accompanied by spastic gait with the degeneration of upper neuron motors and bulbar weakness. There may also be deterioration in vertical saccades; however, there is limited data regarding the same (22).

Among the subtypes of PSP, PSP-RS (40%) is the most common (23). PSPRS was also the most common subtype in our patient group (7/18), and it was followed by PSP-P (20%), PSP-FTD (15%), PSP-CBS (10%), PSP-AOS (5%), and PSP-PAGF (<5%) (6,14,24,25,26). In contrast, other subtypes of PSP are very rare (18,27,28). Although some studies suggest that the commonly used NINDS-SPSP criteria are very sensitive for PSP-RS, they are not very appropriate for detecting other clinical subtypes of PSP (23). Moreover, the existence of two or more PSP variants may seen in a single case. The specificity of clinical syndromes depending on the underlying pathology cause contradictions for diagnosis. Thus, the determination of dominant clinical features and symptoms, which are specific and sensitive to an underlying PSP pathology, is significant to increase the clinical diagnostic precision in atypical phenotypes of PSP.

Our study has some limitations such as a relatively low number of patients, retrospective design, and lack of neuropathological examination of patients with PSP.

CONCLUSION

Conducting future clinicopathological studies with large samples and multiple centers on PSP subtypes will help better understand the etiology of PSP and its specific neurodegenerative mechanisms. Classifying PSP with respect to its phenotypes may be useful for informing clinicians about the diverse clinical presentations of PSP, thereby possibly improving the diagnostic sensitivity of the disease.

Ethics Committee Approval: Ethics committee approval was received for this study from the ethics committee of Erciyes University School of Medicine.

Informed Consent: Written informed consent was obtained from patients who participated in this study.

Peer-review: Externally peer-reviewed.

Conflicts of interest: No conflict of interest was declared by the author.

Financial Disclosure: The author declared that this study has received no financial support.

REFERENCES

1. Lopez G, Bayulkem K, Hallett M. Progressive supranuclear palsy (PSP): Richardson syndrome and other PSP variants. *Acta Neurol Scand* 2016; 4:242-249. [CrossRef]

2. Lang AE. Clinical heterogeneity in progressive supranuclear palsy: challenges to diagnosis, pathogenesis and future therapies. *Mov Disord* 2014; 29:1707–1709. [\[CrossRef\]](#)
3. Litvan I, Agid Y, Calne D, Campbell G, Dubois B, Duvoisin RC, Goetz CG, Golbe LI, Grafman J, Growdon JH, Hallett M, Jankovic J, Quinn NP, Tolosa E, Zee DS. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. *Neurology* 1996; 47:1–9. [\[CrossRef\]](#)
4. Wenning GK, Litvan I, Tolosa E. Milestones in atypical and secondary Parkinsonisms. *Mov Disord* 2011; 26:1083–1095. [\[CrossRef\]](#)
5. Ling H. Clinical Approach to Progressive Supranuclear Palsy. *J Mov Disord* 2016; 9:3–13. [\[CrossRef\]](#)
6. Williams DR, Lees AJ. Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges. *The Lancet Neurology* 2009; 8:270–279. [\[CrossRef\]](#)
7. Kanazawa M, Shimohata T, Toyoshima Y, Tada M, Kakita A, Morita T, Ozawa T, Takahashi H, Nishizawa M. Cerebellar involvement in progressive supranuclear palsy: A clinicopathological study. *Mov Disord* 2009; 24:1312–1318. [\[CrossRef\]](#)
8. Respondek G, Hoglinger GU. The phenotypic spectrum of progressive supranuclear palsy. *Parkinsonism Related Disord* 2016; 22:34–36. [\[CrossRef\]](#)
9. Höglinger GU, Respondek G, Stamelou M, Kurz C, Josephs KA, Lang AE, Mollenhauer B, Müller U, Nilsson C, Whitwell JL, Arzberger T, Englund E, Gelpi E, Giese A, Irwin DJ, Meissner WG, Pantelyat A, Rajput A, van Swieten JC, Troakes C, Antonini A, Bhatia KP, Bordelon Y, Compta Y, Corvol JC, Colosimo C, Dickson DW, Dodel R, Ferguson L, Grossman M, Kassubek J, Krismer F, Levin J, Lorenz S, Morris HR, Nestor P, Oertel WH, Poewe W, Rabinovici G, Rowe JB, Schellenberg GD, Seppi K, van Eimeren T, Wenning GK, Boxer AL, Golbe LI, Litvan I; Movement Disorder Society-endorsed PSP Study Group. Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. *Mov Disord* 2017; 32:853–864. [\[CrossRef\]](#)
10. Dabrowska M, Schinwelski M, Sitek EJ, Muraszko-Klaudel A, Brockhuis B, Jamrozik Z, Slawek J. The role of neuroimaging in the diagnosis of the atypical parkinsonian syndromes in clinical practice. *Neurol Neurochir Pol* 2015; 49:421–431. [\[CrossRef\]](#)
11. Oba H, Yagishita A, Terada H, Barkovich AJ, Kutomi K, Yamauchi T, Furui S, Shimizu T, Uchigata M, Matsumura K, Sonoo M, Sakai M, Takada K, Harasawa A, Takeshita K, Kohtake H, Tanaka H, Suzuki S. New and reliable MRI diagnosis for progressive supranuclear palsy. *Neurology* 2005; 12:2050–2055. [\[CrossRef\]](#)
12. Dugger BN, Adler CH, Shill HA, Caviness J, Jacobson S, Driver-Dunckley E, Beach TG. Concomitant pathologies among a spectrum of parkinsonian disorders. *Parkinsonism Related Disord* 2014; 20:525–529. [\[CrossRef\]](#)
13. O'Sullivan SS, Massey LA, Williams DR, Silveira-Moriyama L, Kempster PA, Holton JL, Revesz T, Lees AJ. Clinical outcomes of progressive supranuclear palsy and multiple system atrophy. *Brain* 2008; 131:1362–1372. [\[CrossRef\]](#)
14. Stamelou M, de Silva R, Arias-Carrion O, Boura E, Hollerhage M, Oertel WH, Müller U, Höglinger GU. Rational therapeutic approaches to progressive supranuclear palsy. *Brain* 2010; 133:1578–1590. [\[CrossRef\]](#)
15. Constantinescu R, Richard I, Kurlan R. Levodopa responsiveness in disorders with parkinsonism: a review of the literature. *Mov Disord* 2007; 22:2141–2148. [\[CrossRef\]](#)
16. Levin J, Kurz A, Arzberger T, Giese A, Hoglinger GU. The differential diagnosis and treatment of atypical parkinsonism. *Dtsch Arztebl Int* 2016; 113:61–69.
17. Rohrer JD, Lashley T, Schott JM, Warren JE, Mead S, Isaacs AM, Beck J, Hardy J, de Silva R, Warrington E, Troakes C, Al-Sarraj S, King A, Borroni B, Clarkson MJ, Ourselin S, Holton JL, Fox NC, Revesz T, Rossor MN, Warren JD. Clinical and neuroanatomical signatures of tissue pathology in frontotemporal lobar degeneration. *Brain* 2011; 134:2565–2581. [\[CrossRef\]](#)
18. Josephs KA, Duffy JR. Apraxia of speech and nonfluent aphasia: a new clinical marker for corticobasal degeneration and progressive supranuclear palsy. *Curr Opin Neurol* 2008; 21:688–692. [\[CrossRef\]](#)
19. Ling H, O'Sullivan SS, Holton JL, Revesz T, Massey LA, Williams DR, Paviour DC, Lees AJ. Does corticobasal degeneration exist? A clinicopathological re-evaluation. *Brain* 2010; 133:2045–2057. [\[CrossRef\]](#)
20. Ling H, de Silva R, Massey LA, Courtney R, Hondhamuni G, Bajaj N, Lowe J, Holton JL, Lees A, Revesz T. Characteristics of progressive supranuclear palsy presenting with corticobasal syndrome: a cortical variant. *Neuropathol Appl Neurobiol* 2014; 40:149–163. [\[CrossRef\]](#)
21. Koga S, Josephs KA, Ogaki K, Labbe C, Uitti RJ, Graff-Radford N, van Gerpen JA, Cheshire WP, Aoki N, Rademakers R, Wszolek ZK, Ross OA, Dickson DW. Cerebellar ataxia in progressive supranuclear palsy: An autopsy study of PSP-C. *Mov Disord* 2016; 31:653–662. [\[CrossRef\]](#)
22. Coon EA, Whitwell JL, Jack CR, Jr., Josephs KA. Primary lateral sclerosis as progressive supranuclear palsy: diagnosis by diffusion tensor imaging. *Mov Disord* 2012; 27:903–906. [\[CrossRef\]](#)
23. Respondek G, Stamelou M, Kurz C, Ferguson LW, Rajput A, Chiu WZ, van Swieten JC, Troakes C, Al Sarraj S, Gelpi E, Gaig C, Tolosa E, Oertel WH, Giese A, Roeber S, Arzberger T, Wagenpfeil S, Höglinger GU; Movement Disorder Society-endorsed PSP Study Group. The phenotypic spectrum of progressive supranuclear palsy: a retrospective multicenter study of 100 definite cases. *Mov Disord* 2014; 29:1758–1766. [\[CrossRef\]](#)
24. Williams DR, de Silva R, Paviour DC, Pittman A, Watt HC, Kilford L, Holton JL, Revesz T, Lees AJ. Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP-parkinsonism. *Brain* 2005; 128: 1247–1258. [\[CrossRef\]](#)
25. Williams DR, Holton JL, Strand K, Revesz T, Lees AJ. Pure akinesia with gait freezing: a third clinical phenotype of progressive supranuclear palsy. *Mov Disord* 2007; 22:2235–2241. [\[CrossRef\]](#)
26. Brown RG, Lacomblez L, Landwehrmeyer BG, Bak T, Uttner I, Dubois B, Agid Y, Ludolph A, Bensimon G, Payan C, Leigh NP; NNIPPS Study Group. Cognitive impairment in patients with multiple system atrophy and progressive supranuclear palsy. *Brain* 2010; 133:2382–2393. [\[CrossRef\]](#)
27. Kanazawa M, Tada M, Onodera O, Takahashi H, Nishizawa M, Shimohata T. Early clinical features of patients with progressive supranuclear palsy with predominant cerebellar ataxia. *Parkinsonism Relat Disord* 2013; 19:1149–1151. [\[CrossRef\]](#)
28. Iwasaki Y, Mori K, Ito M, Tatsumi S, Mimuro M, Yoshida M. An autopsied case of progressive supranuclear palsy presenting with cerebellar ataxia and severe cerebellar involvement. *Neuropathology* 2013; 33:561–567. [\[CrossRef\]](#)